Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical betadine or betamethasone-chloramphenicol for epidemic keratoconjunctivitis
IRCT20250308064985N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of povidone-iodine, betamethasone, chloramphenicol and artificial tears in adenoviral keratoconjunctivitis (EKC) (3 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoints: Clinical symptoms at follow-up and Adverse effects. Started Jun 2025; status: completed.
02
Drugs
povidone-iodinebetamethasonechloramphenicolartificial tears
03
Conditions
adenoviral keratoconjunctivitis (EKC)
Beyond the preview
Go deeper on IRCT20250308064985N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250308064985N1.